The biotech’s IgAN drug has FDA accelerated approval, but ORIGIN 3 results and a Q4 2026 sBLA will decide how durable that runway looks.
Vera’s TRUTAKNA Launch Set Up A High-Stakes Phase 3 Test
The biotech’s IgAN drug has FDA accelerated approval, but ORIGIN 3 results and a Q4 2026 sBLA will decide how durable that runway looks.